Literature DB >> 24219984

How distressing is referral to colposcopy in cervical cancer screening?: a prospective quality of life study.

Ida J Korfage1, Marie-Louise Essink-Bot2, Steven M Westenberg3, Theo Helmerhorst4, J Dik F Habbema5, Marjolein van Ballegooijen5.   

Abstract

OBJECTIVE: Referral for colposcopy because of abnormal Pap test results is likely to be distressing, but the extent and duration of these effects are unknown. We aimed to fill this gap.
METHODS: We conducted a prospective observational study at two departments of Obstetrics and Gynecology (an academic and a non-academic setting). Women referred for colposcopy completed questionnaires before colposcopy, and at 1, 3, and 6 months afterwards. A reference group of 706 screen participants, aged 29-60 years old, was included and completed questionnaires once. Main outcome measures were generic health-related quality of life (HRQoL), assessed through the EQ-5D and the SF-12 physical and mental scores (PCS-12 and MCS-12); anxiety as assessed by STAI-6, and screen-specific anxiety as assessed by the psychological consequences questionnaire (PCQ).
RESULTS: 154 women responded to the questionnaire, of whom 132 were included in the analyses. Histological results were CIN 1 in 17/115 women (15%) and CIN 2+ in 62 (54%). In 36 women (31%) there was no histologically confirmed neoplasia. Before colposcopy physical HRQoL scores were similar or slightly better than in the reference group, while mental HRQoL (MSC-12) and (screen-specific) anxiety were worse (p<0.001). Irrespective of CIN-grades, anxiety washed out during follow-up (p<0.001), with changes being clinically relevant.
CONCLUSIONS: Referral for gynecological evaluation because of abnormal PAP-test results was distressing. Anxiety--and not the physical burden of management--seemed to be the most bothersome to women. For all CIN-grades, distress disappeared over six months following colposcopy, suggesting a reassuring effect of gynecological management.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abnormal Pap; CIN; Cervical cancer; Longitudinal; Quality of life; Screening

Mesh:

Year:  2013        PMID: 24219984     DOI: 10.1016/j.ygyno.2013.11.001

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

1.  Excess Cost of Cervical Cancer Screening Beyond Recommended Screening Ages or After Hysterectomy in a Single Institution.

Authors:  Deanna Teoh; Gretchen Hultman; McKenzie DeKam; Rachel Isaksson Vogel; Levi S Downs; Melissa A Geller; Chap Le; Genevieve Melton; Shalini Kulasingam
Journal:  J Low Genit Tract Dis       Date:  2018-07       Impact factor: 1.925

2.  The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making.

Authors:  Kevin Koo; Lisa Zubkoff; Brenda E Sirovich; Philip P Goodney; Douglas J Robertson; John D Seigne; Florian R Schroeck
Journal:  Urology       Date:  2017-07-21       Impact factor: 2.649

Review 3.  Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review.

Authors:  A Ó Céilleachair; J F O'Mahony; M O'Connor; J O'Leary; C Normand; C Martin; L Sharp
Journal:  Qual Life Res       Date:  2017-06-26       Impact factor: 4.147

4.  Primary care visit use after positive fecal immunochemical test for colorectal cancer screening.

Authors:  Grace Clarke Hillyer; Christopher D Jensen; Wei K Zhao; Alfred I Neugut; Benjamin Lebwohl; Jasmin A Tiro; Lawrence H Kushi; Douglas A Corley
Journal:  Cancer       Date:  2017-06-16       Impact factor: 6.860

5.  Cervical cancer worry and screening among appalachian women.

Authors:  Kimberly M Kelly; Nancy Schoenberg; Tomorrow D Wilson; Elvonna Atkins; Stephanie Dickinson; Electra Paskett
Journal:  J Prim Prev       Date:  2015-04

6.  Health-related quality of life in women after colposcopy: results from a longitudinal patient survey.

Authors:  M O'Connor; A Ó Céilleachair; K O'Brien; J O'Leary; C Martin; T D'Arcy; G Flannelly; J McRae; W Prendiville; C Ruttle; C White; L Pilkington; L Sharp
Journal:  Qual Life Res       Date:  2021-04-01       Impact factor: 4.147

7.  Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.

Authors:  Jane J Kim; Emily A Burger; Stephen Sy; Nicole G Campos
Journal:  J Natl Cancer Inst       Date:  2016-10-18       Impact factor: 13.506

8.  Adherence to the 2012 national cervical cancer screening guidelines: a pilot study.

Authors:  Deanna G K Teoh; Amity E Marriott; Rachel Isaksson Vogel; Ryan T Marriott; Charles W Lais; Levi S Downs; Shalini L Kulasingam
Journal:  Am J Obstet Gynecol       Date:  2014-06-30       Impact factor: 8.661

9.  Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.

Authors:  Sæmundur Rögnvaldsson; Thorvardur Jon Love; Sigrun Thorsteinsdottir; Elín Ruth Reed; Jón Þórir Óskarsson; Íris Pétursdóttir; Guðrún Ásta Sigurðardóttir; Brynjar Viðarsson; Páll Torfi Önundarson; Bjarni A Agnarsson; Margrét Sigurðardóttir; Ingunn Þorsteinsdóttir; Ísleifur Ólafsson; Ásdís Rósa Þórðardóttir; Elías Eyþórsson; Ásbjörn Jónsson; Andri S Björnsson; Gunnar Þór Gunnarsson; Runólfur Pálsson; Ólafur Skúli Indriðason; Gauti Kjartan Gíslason; Andri Ólafsson; Guðlaug Katrín Hákonardóttir; Manje Brinkhuis; Sara Lovísa Halldórsdóttir; Tinna Laufey Ásgeirsdóttir; Hlíf Steingrímsdóttir; Ragnar Danielsen; Inga Dröfn Wessman; Petros Kampanis; Malin Hulcrantz; Brian G M Durie; Stephen Harding; Ola Landgren; Sigurður Yngvi Kristinsson
Journal:  Blood Cancer J       Date:  2021-05-17       Impact factor: 11.037

10.  Development and validation of a clinical prediction model for endocervical curettage decision-making in cervical lesions.

Authors:  Yuanxing Li; Haixia Luo; Xiu Zhang; Jingjing Chang; Yueyang Zhao; Jing Li; Dongyan Li; Wei Wang
Journal:  BMC Cancer       Date:  2021-07-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.